Review summary
Teaching objective: Diagnose and manage stage G3a A2 chronic kidney disease with hypertension in a 54-year-old woman by KDIGO 2024 and the CMID kidney and blood pressure schedules: eGFR and albuminuria staging, KFRE, a maximum-dose ARB and an SGLT2 inhibitor with potassium and creatinine checks after each start, a statin, bone-mineral and anemia checks by stage, vaccines, NSAID avoidance, and sick-day guidance, while screening mood and anxiety without labeling a lifelong wish for solitude as a disorder, and delivering care at home or by video where that is safe.
Historical timeline
| Date | Event | Claims |
|---|---|---|
| December 10, 1830 | Born in the family Homestead in Amherst, Massachusetts. | CLM-0001 |
| Late winter of 1848 | Removed from Mount Holyoke Female Seminary for about a month with lung congestion and a cough. | CLM-0002 |
| 1851 | Consumptive symptoms; takes a glycerine prescription for two years. | CLM-0003 |
| Fall of 1863 | Eye affliction begins. | CLM-0004 |
| February 1864 | Consults a Boston ophthalmologist; treated while living in Cambridgeport from April to December. | CLM-0004, CLM-0005 |
| April to October 1865 | Repeats the eye treatment and is apparently cured. | CLM-0004 |
| October 1883 | Nervous prostration after a death in her family; ill health continues to her death. | CLM-0010 |
| May 15, 1886 | Dies in Amherst at 55; Bright's disease is entered on the death certificate. | CLM-0013 |
Evidence claims
D = documented, R = retrospective, S = synthetic.
| Grade | Claim | Certainty | Sources |
|---|---|---|---|
| D | Emily Dickinson was born on December 10, 1830, in the family Homestead on Main Street in Amherst, Massachusetts. | confirmed | Emily Dickinson: Her Childhood and Youth (1830-1855) supports |
| D | In the late winter of 1848 she was removed from Mount Holyoke Female Seminary for about a month because of lung congestion and a cough. | confirmed | Emily Dickinson's Health supports |
| D | In 1851 she had symptoms then thought to be consumptive, consulted local and Boston doctors, and for two years took a glycerine prescription from a Boston tuberculosis specialist until the symptoms apparently subsided. No diagnosis of tuberculosis is documented. |
confirmed | Emily Dickinson's Health supports |
| D | By her own account an eye affliction began in the fall of 1863; in February 1864 she consulted the Boston ophthalmologist Henry Willard Williams, lived in Cambridgeport from April to December 1864 to be near him for treatment, and repeated the treatment from April to October 1865, after which she was apparently cured. | confirmed | Emily Dickinson's Health supports Blanchard DL. Emily Dickinson's ophthalmic consultation with Henry Willard Williams, MD. Arch Ophthalmol. 2012;130(12):1591-1595. doi:10.1001/archophthalmol.2012.2365 supports |
| D | The treatment required confinement in dim light, no reading, and writing only in pencil; she called her first stay in Cambridge eight months of Siberia. | confirmed | Emily Dickinson's Health supports |
| R | No record of the eye diagnosis survives. Her main symptoms were sensitivity to light, aching eyes, and a restricted ability to do close work; iritis is considered the most likely explanation, and exotropia, a psychiatric cause, and hysterical hyperaesthesia of the retina have also been proposed. Retrospective interpretations; the 2012 review offers a further possibility rather than a conclusion. |
disputed | Blanchard DL. Emily Dickinson's ophthalmic consultation with Henry Willard Williams, MD. Arch Ophthalmol. 2012;130(12):1591-1595. doi:10.1001/archophthalmol.2012.2365 supports Emily Dickinson's Health supports |
| D | Her withdrawal from normal social situations began in her mid-twenties; in later years she rarely went beyond the family Homestead and spoke with some visitors from behind a darkened door rather than face to face. | confirmed | Emily Dickinson's Health supports Emily Dickinson: The Later Years (1865-1886) supports |
| R | Scholars disagree whether her withdrawal was a deliberate artistic choice or had a medical origin, such as an anxiety condition. No diagnosis is documented; labels such as agoraphobia or social anxiety are retrospective and disputed. |
disputed | Emily Dickinson's Health supports |
| R | A 2013 review by Hirschhorn and Longsworth rejects a proposed diagnosis of epilepsy on scientific, clinical, and biographical grounds. Retrospective debate; epilepsy is not used in the record. |
disputed | Hirschhorn N, Longsworth P. Was it epilepsy?: misdiagnosing Emily Dickinson (1830-1886). Perspect Biol Med. 2013;56(3):371-386. doi:10.1353/pbm.2013.0026 supports |
| D | Her death came after two and a half years of ill health that followed a death in her family in October 1883 and a consequent nervous prostration; she later had two blackouts and was confined to bed for the seven months before her death. Nervous prostration is a nineteenth-century term, not a modern diagnosis. |
confirmed | Emily Dickinson and Death supports Emily Dickinson: The Later Years (1865-1886) supports |
| D | Her letters mention severe headache and nausea, and her last illness ended in a coma with raspy, difficult breathing. | confirmed | Emily Dickinson and Death supports |
| D | Her reclusiveness hampered her Amherst physician, because she would not admit him to her bedside to take a pulse. | confirmed | Emily Dickinson and Death supports |
| D | She died in Amherst on May 15, 1886, aged 55; her physician entered Bright's disease as the cause on her death certificate, at the time a general diagnosis that included hypertensive symptoms as well as nephritis. Bright's disease was a broad nineteenth-century label, not a specific modern kidney diagnosis. |
confirmed | Emily Dickinson and Death supports Emily Dickinson: The Later Years (1865-1886) supports |
| R | Researchers have concluded that she died of heart failure caused by severe hypertension; no documentary evidence records the yellow pallor and odor associated with nephritis. A retrospective interpretation; no blood pressure or kidney test from her lifetime exists. |
possible | Emily Dickinson and Death supports |
Modern synthetic problem list
| Grade | Problem | Clinical status | Verification | Placement | Historical claims |
|---|---|---|---|---|---|
| S | Chronic kidney disease stage G3a A2, attributed to hypertension; synthetic modern diagnosis linked to the Bright's disease entered on her death certificate | active | confirmed | both_with_link | CLM-0013, CLM-0014 |
| S | Hypertension with chronic kidney disease (hypertensive chronic kidney disease, stage 3a); synthetic modern diagnosis linked to the retrospective view that she had severe hypertension | active | confirmed | both_with_link | CLM-0014, CLM-0011 |
| S | Vitamin D deficiency with a mildly raised PTH in chronic kidney disease | active | confirmed | active | |
| S | Viral gastroenteritis with volume depletion and a prerenal rise in creatinine while taking losartan and dapagliflozin; resolved | resolved | confirmed | active |
Synthetic outcome measures
| Grade | Date | Measure | Result | Coding |
|---|---|---|---|---|
| S | 2026-01-12 | Sodium [Moles/volume] in Serum or Plasma | 139 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-01-12 | Potassium [Moles/volume] in Serum or Plasma | 4.4 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-01-12 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 24 mmol/L Reference 22-29 mmol/L |
http://loinc.org · 2028-9 |
| S | 2026-01-12 | Urea nitrogen [Mass/volume] in Serum or Plasma | 21 mg/dL Reference 6-21 mg/dL |
http://loinc.org · 3094-0 |
| S | 2026-01-12 | Creatinine [Mass/volume] in Serum or Plasma | 1.2 mg/dL (high) Reference 0.59-1.04 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-01-12 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 54 mL/min/1.73 m² (low) Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-01-12 | Glucose [Mass/volume] in Serum or Plasma | 92 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2026-01-12 | Calcium [Mass/volume] in Serum or Plasma | 9.3 mg/dL Reference 8.6-10.3 mg/dL |
http://loinc.org · 17861-6 |
| S | 2026-01-12 | Phosphate [Mass/volume] in Serum or Plasma | 3.8 mg/dL Reference 2.5-4.5 mg/dL |
http://loinc.org · 2777-1 |
| S | 2026-01-12 | Parathyrin.intact [Mass/volume] in Serum or Plasma | 74 pg/mL (high) Reference 15-65 pg/mL |
http://loinc.org · 2731-8 |
| S | 2026-01-12 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 21 ng/mL (low) Reference 30-100 ng/mL |
http://loinc.org · 62292-8 |
| S | 2026-01-12 | Albumin [Mass/volume] in Serum or Plasma | 4.1 g/dL Reference 3.5-5 g/dL |
http://loinc.org · 1751-7 |
| S | 2026-01-12 | Hemoglobin [Mass/volume] in Blood | 12.3 g/dL Reference 12-15.5 g/dL |
http://loinc.org · 718-7 |
| S | 2026-01-12 | Cholesterol [Mass/volume] in Serum or Plasma | 214 mg/dL (high) Reference <=199 mg/dL |
http://loinc.org · 2093-3 |
| S | 2026-01-12 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 54 mg/dL Reference >=50 mg/dL |
http://loinc.org · 2085-9 |
| S | 2026-01-12 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 134 mg/dL (high) Reference <=99 mg/dL |
http://loinc.org · 13457-7 |
| S | 2026-01-12 | Triglyceride [Mass/volume] in Serum or Plasma | 130 mg/dL Reference <=149 mg/dL |
http://loinc.org · 2571-8 |
| S | 2026-01-12 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.5% Reference <=5.6% |
http://loinc.org · 4548-4 |
| S | 2026-01-12 | Thyrotropin [Units/volume] in Serum or Plasma | 2.1 mIU/L Reference 0.4-4 mIU/L |
http://loinc.org · 3016-3 |
| S | 2026-01-12 | Albumin/Creatinine [Mass Ratio] in Urine | 240 mg/g (high) Reference <=30 mg/g |
http://loinc.org · 9318-7 |
| S | 2026-01-12 | Erythrocytes [#/area] in Urine sediment by Microscopy high power field | 1 /[HPF] Reference <=2 /[HPF] |
http://loinc.org · 13945-1 |
| S | 2026-01-12 | Kidney failure 2-year risk [Likelihood] by KFRE | 0.5% | http://loinc.org · 85624-5 |
| S | 2026-01-12 | Kidney failure 5-year risk [Likelihood] by KFRE | 1.6% | http://loinc.org · 85625-2 |
| S | 2026-01-12 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | http://loinc.org · 44261-6 |
| S | 2026-01-12 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 5 | http://loinc.org · 70274-6 |
| S | 2026-02-02 | Sodium [Moles/volume] in Serum or Plasma | 140 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-02-02 | Potassium [Moles/volume] in Serum or Plasma | 4.6 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-02-02 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 24 mmol/L Reference 22-29 mmol/L |
http://loinc.org · 2028-9 |
| S | 2026-02-02 | Urea nitrogen [Mass/volume] in Serum or Plasma | 22 mg/dL (high) Reference 6-21 mg/dL |
http://loinc.org · 3094-0 |
| S | 2026-02-02 | Creatinine [Mass/volume] in Serum or Plasma | 1.26 mg/dL (high) Reference 0.59-1.04 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-02-02 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 51 mL/min/1.73 m² (low) Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-02-02 | Glucose [Mass/volume] in Serum or Plasma | 90 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2026-02-02 | Albumin/Creatinine [Mass Ratio] in Urine | 262 mg/g (high) Reference <=30 mg/g |
http://loinc.org · 9318-7 |
| S | 2026-03-02 | Sodium [Moles/volume] in Serum or Plasma | 139 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-03-02 | Potassium [Moles/volume] in Serum or Plasma | 4.8 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-03-02 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 23 mmol/L Reference 22-29 mmol/L |
http://loinc.org · 2028-9 |
| S | 2026-03-02 | Urea nitrogen [Mass/volume] in Serum or Plasma | 23 mg/dL (high) Reference 6-21 mg/dL |
http://loinc.org · 3094-0 |
| S | 2026-03-02 | Creatinine [Mass/volume] in Serum or Plasma | 1.32 mg/dL (high) Reference 0.59-1.04 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-03-02 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 48 mL/min/1.73 m² (low) Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-03-02 | Glucose [Mass/volume] in Serum or Plasma | 88 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2026-06-01 | Sodium [Moles/volume] in Serum or Plasma | 140 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-06-01 | Potassium [Moles/volume] in Serum or Plasma | 4.7 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-06-01 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 24 mmol/L Reference 22-29 mmol/L |
http://loinc.org · 2028-9 |
| S | 2026-06-01 | Urea nitrogen [Mass/volume] in Serum or Plasma | 22 mg/dL (high) Reference 6-21 mg/dL |
http://loinc.org · 3094-0 |
| S | 2026-06-01 | Creatinine [Mass/volume] in Serum or Plasma | 1.3 mg/dL (high) Reference 0.59-1.04 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-06-01 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 49 mL/min/1.73 m² (low) Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-06-01 | Glucose [Mass/volume] in Serum or Plasma | 91 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2026-06-01 | Albumin/Creatinine [Mass Ratio] in Urine | 118 mg/g (high) Reference <=30 mg/g |
http://loinc.org · 9318-7 |
| S | 2026-06-01 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | http://loinc.org · 44261-6 |
| S | 2026-09-28 | Sodium [Moles/volume] in Serum or Plasma | 139 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-09-28 | Potassium [Moles/volume] in Serum or Plasma | 4.6 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-09-28 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 25 mmol/L Reference 22-29 mmol/L |
http://loinc.org · 2028-9 |
| S | 2026-09-28 | Urea nitrogen [Mass/volume] in Serum or Plasma | 21 mg/dL Reference 6-21 mg/dL |
http://loinc.org · 3094-0 |
| S | 2026-09-28 | Creatinine [Mass/volume] in Serum or Plasma | 1.28 mg/dL (high) Reference 0.59-1.04 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-09-28 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 50 mL/min/1.73 m² (low) Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-09-28 | Glucose [Mass/volume] in Serum or Plasma | 90 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2026-09-28 | Albumin/Creatinine [Mass Ratio] in Urine | 96 mg/g (high) Reference <=30 mg/g |
http://loinc.org · 9318-7 |
| S | 2026-09-28 | Calcium [Mass/volume] in Serum or Plasma | 9.4 mg/dL Reference 8.6-10.3 mg/dL |
http://loinc.org · 17861-6 |
| S | 2026-09-28 | Phosphate [Mass/volume] in Serum or Plasma | 3.6 mg/dL Reference 2.5-4.5 mg/dL |
http://loinc.org · 2777-1 |
| S | 2026-09-28 | Parathyrin.intact [Mass/volume] in Serum or Plasma | 61 pg/mL Reference 15-65 pg/mL |
http://loinc.org · 2731-8 |
| S | 2026-09-28 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 36 ng/mL Reference 30-100 ng/mL |
http://loinc.org · 62292-8 |
| S | 2026-04-20 | Sodium [Moles/volume] in Serum or Plasma | 136 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-04-20 | Potassium [Moles/volume] in Serum or Plasma | 5.3 mmol/L (high) Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-04-20 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 20 mmol/L (low) Reference 22-29 mmol/L |
http://loinc.org · 2028-9 |
| S | 2026-04-20 | Urea nitrogen [Mass/volume] in Serum or Plasma | 34 mg/dL (high) Reference 6-21 mg/dL |
http://loinc.org · 3094-0 |
| S | 2026-04-20 | Creatinine [Mass/volume] in Serum or Plasma | 1.66 mg/dL (high) Reference 0.59-1.04 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-04-20 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 36 mL/min/1.73 m² (low) Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-04-20 | Glucose [Mass/volume] in Serum or Plasma | 86 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2026-10-19 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | http://loinc.org · 55758-7 |
| S | 2026-10-19 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 3 | http://loinc.org · 70274-6 |
| S | 2026-10-19 | Total score [AUDIT-C] | 0 | http://loinc.org · 75626-2 |
Synthetic vital signs
| Date | Measure | Result | LOINC | Grade |
|---|---|---|---|---|
| 2026-01-12 | Body height | 163 cm | 8302-2 | S |
| 2026-01-12 | Body weight | 54 kg | 29463-7 | S |
| 2026-01-12 | Body mass index (BMI) [Ratio] | 20.3 kg/m2 | 39156-5 | S |
| 2026-01-12 | Systolic blood pressure | 166 mm[Hg] | 8480-6 | S |
| 2026-01-12 | Diastolic blood pressure | 98 mm[Hg] | 8462-4 | S |
| 2026-01-12 | Heart rate | 78 /min | 8867-4 | S |
| 2026-01-12 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-01-12 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-01-12 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-02-02 | Body height | 163 cm | 8302-2 | S |
| 2026-02-02 | Body weight | 53.8 kg | 29463-7 | S |
| 2026-02-02 | Body mass index (BMI) [Ratio] | 20.2 kg/m2 | 39156-5 | S |
| 2026-02-02 | Systolic blood pressure | 148 mm[Hg] | 8480-6 | S |
| 2026-02-02 | Diastolic blood pressure | 88 mm[Hg] | 8462-4 | S |
| 2026-02-02 | Heart rate | 74 /min | 8867-4 | S |
| 2026-02-02 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-02-02 | Body temperature | 36.5 Cel | 8310-5 | S |
| 2026-02-02 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-03-02 | Body height | 163 cm | 8302-2 | S |
| 2026-03-02 | Body weight | 53.6 kg | 29463-7 | S |
| 2026-03-02 | Body mass index (BMI) [Ratio] | 20.2 kg/m2 | 39156-5 | S |
| 2026-03-02 | Systolic blood pressure | 136 mm[Hg] | 8480-6 | S |
| 2026-03-02 | Diastolic blood pressure | 84 mm[Hg] | 8462-4 | S |
| 2026-03-02 | Heart rate | 72 /min | 8867-4 | S |
| 2026-03-02 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-03-02 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-03-02 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-04-20 | Body height | 163 cm | 8302-2 | S |
| 2026-04-20 | Body weight | 51.9 kg | 29463-7 | S |
| 2026-04-20 | Body mass index (BMI) [Ratio] | 19.5 kg/m2 | 39156-5 | S |
| 2026-04-20 | Systolic blood pressure | 104 mm[Hg] | 8480-6 | S |
| 2026-04-20 | Diastolic blood pressure | 64 mm[Hg] | 8462-4 | S |
| 2026-04-20 | Heart rate | 102 /min | 8867-4 | S |
| 2026-04-20 | Respiratory rate | 18 /min | 9279-1 | S |
| 2026-04-20 | Body temperature | 37.6 Cel | 8310-5 | S |
| 2026-04-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 % | 59408-5 | S |
| 2026-06-01 | Body height | 163 cm | 8302-2 | S |
| 2026-06-01 | Body weight | 53.2 kg | 29463-7 | S |
| 2026-06-01 | Body mass index (BMI) [Ratio] | 20 kg/m2 | 39156-5 | S |
| 2026-06-01 | Systolic blood pressure | 124 mm[Hg] | 8480-6 | S |
| 2026-06-01 | Diastolic blood pressure | 76 mm[Hg] | 8462-4 | S |
| 2026-06-01 | Heart rate | 70 /min | 8867-4 | S |
| 2026-06-01 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-06-01 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-06-01 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-09-28 | Body height | 163 cm | 8302-2 | S |
| 2026-09-28 | Body weight | 53.4 kg | 29463-7 | S |
| 2026-09-28 | Body mass index (BMI) [Ratio] | 20.1 kg/m2 | 39156-5 | S |
| 2026-09-28 | Systolic blood pressure | 118 mm[Hg] | 8480-6 | S |
| 2026-09-28 | Diastolic blood pressure | 74 mm[Hg] | 8462-4 | S |
| 2026-09-28 | Heart rate | 68 /min | 8867-4 | S |
| 2026-09-28 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-09-28 | Body temperature | 36.5 Cel | 8310-5 | S |
| 2026-09-28 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-10-19 | Body height | 163 cm | 8302-2 | S |
| 2026-10-19 | Body weight | 53.5 kg | 29463-7 | S |
| 2026-10-19 | Body mass index (BMI) [Ratio] | 20.1 kg/m2 | 39156-5 | S |
| 2026-10-19 | Systolic blood pressure | 120 mm[Hg] | 8480-6 | S |
| 2026-10-19 | Diastolic blood pressure | 74 mm[Hg] | 8462-4 | S |
| 2026-10-19 | Heart rate | 70 /min | 8867-4 | S |
| 2026-10-19 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-10-19 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-10-19 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
Social, functional, and mental status
Social history
- S Occupation: poet; writes at home most mornings and keeps a large correspondence by letter and email
- S Never smoker; no alcohol; no other substance use
- S Gardens and bakes; walks in her own garden most days but rarely farther
- S Lives in her long-time family home with another adult household member who runs errands and drives when needed; no one is named
- S Has long wished to stay at home and see few visitors; she is comfortable at home and in her garden, but large rooms, crowds, waiting rooms, and travel tire and unsettle her, and she asks for care at home or by video where possible
- S Supports: her household, a few close friends she writes to often, and her work
Functional status
- S At intake, independent in all activities of daily living; headaches and tiredness cut her writing mornings short on most days
- S Writing full mornings again and free of regular headaches by the six-month review
Mental status
- S Alert, precise, and articulate; quiet voice; answers fully but briefly and prefers to add details in writing
- S Mood "tired, not sad"; affect reactive with dry humor; no suicidal ideation; cognition intact
Allergies and medications
Allergies
- S No known allergy
Medications
- S Naproxen sodium 220 mg oral tablet, two tablets by mouth as needed for headache (over the counter)
- S Losartan 50 mg oral tablet, one tablet by mouth daily
- S Losartan 100 mg oral tablet, one tablet by mouth daily
- S Atorvastatin 20 mg oral tablet, one tablet by mouth daily
- S Cholecalciferol (vitamin D3) 25 mcg (1,000 units) oral tablet, one tablet by mouth daily
- S Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for headache, no more than 3 g a day
- S Dapagliflozin 10 mg oral tablet, one tablet by mouth daily
- S Amlodipine 5 mg oral tablet, one tablet by mouth daily
Procedures and immunizations
Procedures
- S 12-lead electrocardiogram at the home visit: sinus rhythm, borderline voltage criteria for left ventricular hypertrophy
- S Kidney ultrasound: right kidney 10.1 cm, left 10.3 cm, with mildly increased cortical echogenicity; no hydronephrosis, stones, or cysts; bladder normal
- S Advance care planning conversation, about 20 minutes
Immunizations
- S 2025-10-20: Influenza vaccine, 2025-2026 season
- S 2019-05-14: Tdap vaccine
- S 2026-01-12: Pneumococcal conjugate vaccine PCV20, given at the home visit
- S 2026-06-01: Hepatitis B vaccine, CpG-adjuvanted (HepB-CpG), dose 1 of 2
- S 2026-10-19: Hepatitis B vaccine, CpG-adjuvanted (HepB-CpG), dose 2 of 2
- S 2026-10-19: Influenza vaccine, 2026-2027 season
- S 2026-10-19: Recombinant zoster vaccine, dose 1 of 2
Past medical history
True biography with historical dates; not part of the synthetic care timeline.
- D Late winter of 1848: Lung congestion and cough; removed from her seminary for about a month (CLM-0002)
- D 1851: Symptoms then thought to be consumptive, treated with a glycerine prescription for about two years until they subsided; no tuberculosis diagnosis is documented (CLM-0003)
- R 1863 to 1865: Eye affliction with sensitivity to light and aching eyes, treated by a Boston ophthalmologist with dim light and no reading during two long stays in Cambridgeport; apparently cured. The diagnosis is not recorded (iritis most often proposed) (CLM-0004, CLM-0005, CLM-0006)
- D October 1883: Nervous prostration after a death in her family, followed by continuing ill health (CLM-0010)
Family history
No family medical history is documented in the logged sources. Family history of real relatives is never synthesized.
Care-plan goals
| Goal | Target date | Status | Outcome |
|---|---|---|---|
| Systolic blood pressure below 120 mmHg (KDIGO), and at least below 130/80, without lightheadedness | 2026-09-28 | completed | 118/74 mmHg on losartan 100 mg and amlodipine 5 mg |
| Urine albumin-creatinine ratio down by at least 30 percent from baseline on an ARB and an SGLT2 inhibitor | 2026-06-01 | completed | 118 mg/g at three months and 96 mg/g at six months, from 240 mg/g |
| Stable kidney function, with no fall in eGFR of more than 20 percent after the expected early dip | 2026-09-28 | active | eGFR 50 at the six-month review (54 at baseline); a temporary fall to 36 during gastroenteritis recovered |
| 25-hydroxyvitamin D of at least 30 ng/mL | 2026-09-28 | completed | 36 ng/mL on vitamin D3; PTH 61 pg/mL |
| Care delivered at home or by video wherever safe, with clinic trips limited to tests that need the clinic | 2026-09-28 | completed | Two clinic trips in the episode, each combining several tasks; all other visits at home or by video |
Interventions
| Intervention | Status | Guideline |
|---|---|---|
| Start losartan 50 mg daily and raise it to the maximum dose of 100 mg for A2 albuminuria; check potassium and creatinine 2 to 4 weeks after each start or increase, accepting a creatinine rise of up to 30 percent | completed | GL-CMID-2026, GL-KDIGO-CKD-2024, GL-KDIGO-BP-2021 |
| If a second sample confirms a urine albumin-creatinine ratio of at least 200 mg/g, add an SGLT2 inhibitor (dapagliflozin 10 mg daily) after the nephrology review, and check potassium and creatinine 2 to 4 weeks later | completed | GL-CMID-2026, GL-KDIGO-CKD-2024 |
| Stop naproxen and avoid all NSAIDs; acetaminophen for headache; check kidney function before any iodinated contrast; adjust drug doses to eGFR | completed | GL-CMID-2026, GL-KDIGO-CKD-2024 |
| Nephrology consultation to confirm the cause of chronic kidney disease with albuminuria in a woman in her fifties and to advise on treatment and follow-up | completed | GL-CMID-2026, GL-KDIGO-CKD-2024 |
| Sick-day guidance: during vomiting, diarrhea, or poor fluid intake, pause losartan, dapagliflozin, and any other blood pressure medicine, drink fluids, call the clinic, and restart after 24 to 48 hours of normal eating and drinking | completed | GL-CMID-2026, GL-KDIGO-CKD-2024 |
| CMID kidney and blood pressure monitoring: blood pressure every visit with home readings; eGFR and urine albumin twice a year at G3a A2; a metabolic panel with each draw; calcium, phosphate, and PTH every 6 to 12 months; vitamin D at baseline; hemoglobin and KFRE yearly; one lipid panel and a statin; medication review every visit; vaccines reviewed yearly | completed | GL-CMID-2026, GL-KDIGO-CKD-2024, GL-ACC-HTN-2017 |
| Atorvastatin 20 mg daily; vitamin D3 1,000 units daily with recheck of 25-hydroxyvitamin D, calcium, phosphate, and PTH | completed | GL-CMID-2026, GL-KDIGO-CKD-2024 |
| Vaccines for chronic kidney disease: PCV20 now, a two-dose hepatitis B series, and yearly influenza and COVID-19 vaccines | completed | GL-CMID-2026, GL-KDIGO-CKD-2024, GL-CDC-IMZ-2026 |
| Home-centered care: home visits and video visits with her own validated blood pressure cuff, scale, thermometer, and pulse oximeter; mobile phlebotomy; clinic trips only for tests that need them, with several tasks booked on one quiet early appointment | completed | GL-CMID-2026, GL-KDIGO-CKD-2024 |
| PHQ-9 and GAD-7 at baseline and yearly; her long-standing wish for solitude is respected and not treated as a disorder unless symptoms cause distress or impairment | completed | GL-CMID-2026, GL-USPSTF-ANX-2023, GL-USPSTF-DEP-2023 |
| Sodium below 2 g a day, a plant-rich diet, and at least 150 minutes a week of activity, such as garden work and walking | completed | GL-CMID-2026, GL-KDIGO-CKD-2024, GL-ACC-HTN-2017 |
Planned encounters
- 2026-01-12 — Primary care home visit for headaches, nausea, and tiredness, with raised blood pressure and abnormal kidney tests (ENC-001)
- 2026-02-02 — Three-week kidney and blood pressure review in the clinic, combined with nephrology consultation and kidney ultrasound on one trip (ENC-002)
- 2026-03-02 — Video visit four weeks after the losartan increase and dapagliflozin start, with home vital signs and home blood tests (ENC-003)
- 2026-04-20 — Same-day home sick visit for vomiting and diarrhea (ENC-004, unscheduled)
- 2026-06-01 — Home visit for the three-month kidney and blood pressure review (ENC-005)
- 2026-09-28 — Video visit for the six-month kidney review, with home vital signs and home blood tests (ENC-006)
- 2026-10-19 — Periodic adult preventive visit (ENC-007)
Supporting documents
- History and physical
- Progress note 01
- Progress note 02 — Focused Visit (Follow-up)
- Progress note 03 — Focused Visit (Follow-up)
- Progress note 04 — Sick Visit
- Progress note 05 — Focused Visit (Follow-up)
- Progress note 06 — Focused Visit (Care-plan review)
- Progress note 07 — Preventive Visit
- Nephrology referral
- Nephrology consultation
- Patient care plan
- Teaching note
- Provenance CSV
C-CDA note documents
Each link opens a readable copy; the XML beside it is the exchange file.
- History and physical (XML)
- Progress note 01 (XML)
- Progress note 02 — Focused Visit (Follow-up) (XML)
- Progress note 03 — Focused Visit (Follow-up) (XML)
- Progress note 04 — Sick Visit (XML)
- Progress note 05 — Focused Visit (Follow-up) (XML)
- Progress note 06 — Focused Visit (Care-plan review) (XML)
- Progress note 07 — Preventive Visit (XML)
- Nephrology referral (XML)
- Nephrology consultation (XML)
Sources
| ID | Source | Publisher | Type |
|---|---|---|---|
| SRC-0001 | Emily Dickinson: Her Childhood and Youth (1830-1855) | Emily Dickinson Museum | other |
| SRC-0002 | Emily Dickinson's Health | Emily Dickinson Museum | other |
| SRC-0003 | Emily Dickinson: The Later Years (1865-1886) | Emily Dickinson Museum | other |
| SRC-0004 | Emily Dickinson and Death | Emily Dickinson Museum | other |
| SRC-0005 | Blanchard DL. Emily Dickinson's ophthalmic consultation with Henry Willard Williams, MD. Arch Ophthalmol. 2012;130(12):1591-1595. doi:10.1001/archophthalmol.2012.2365 | PubMed (PMID 23229703) | scholarly |
| SRC-0006 | Hirschhorn N, Longsworth P. Was it epilepsy?: misdiagnosing Emily Dickinson (1830-1886). Perspect Biol Med. 2013;56(3):371-386. doi:10.1353/pbm.2013.0026 | PubMed (PMID 24375119) | scholarly |
| SRC-0007 | HISTMED Master Roster v3 | The Human Record project | other |
Review status
| Review | Status | Notes |
|---|---|---|
| schema validation | not_started | Run scripts/build.ps1 -Conformance. |
| clinical review | not_started | Awaiting clinician review; check ARB titration and SGLT2 inhibitor use without diabetes, the sick-day plan, home and video vital signs, and the recorded deviation. |
| provenance review | not_started | Four Emily Dickinson Museum pages and two PubMed abstracts logged. Bright's disease on the death certificate is D; hypertensive heart failure, iritis, anxiety, and epilepsy are R. Family history is left empty so that no health facts are attributed to her relatives. |
| safe messaging review | not_started | Mood and anxiety screens are below the thresholds for a safety assessment; her withdrawal is not labeled a disorder; her death is recorded without graphic detail. |
Comments and corrections
Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.
Comments appear on the online version of this page.